Drug Information

Drug General Information
Drug ID
D05RMW
Former ID
DCL001042
Drug Name
ZD-3638
Drug Type
Small molecular drug
Indication Schizophrenia [ICD9: 295; ICD10:F20] Terminated [536463]
Company
AstraZeneca
Formula
C28H30N2O2S
Canonical SMILES
CCS(=O)C1=C(C=CC=N1)C2(CCN(CC2)CC34CC(C5=CC=CC=C53)C6=C<br />C=CC=C46)O
InChI
1S/C28H30N2O2S/c1-2-33(32)26-25(12-7-15-29-26)28(31)13-16-30(17-14-28)19-27-18-22(20-8-3-5-10-23(20)27)21-9-4-6-11-24(21)27/h3-12,15,22,31H,2,13-14,16-19H2,1H3
InChIKey
LVMVFEHQMHETDS-UHFFFAOYSA-N
CAS Number
CAS 152352-44-8
PubChem Compound ID
9955820
PubChem Substance ID
14931442, 14959603, 24225125, 46052428, 78299722, 85210079, 103235722, 128547464, 134339463, 137251295, 227390210
SuperDrug ATC ID
J01FA10
SuperDrug CAS ID
cas=083905015
Target and Pathway
Target(s) 5-hydroxytryptamine 2A receptor Target Info Binder [536463]
D(1B) dopamine receptor Target Info Binder [536463]
D(2) dopamine receptor Target Info Binder [536463]
KEGG Pathway Calcium signaling pathway
Neuroactive ligand-receptor interaction
Gap junction
Serotonergic synapse
Inflammatory mediator regulation of TRP channelshsa04020:Calcium signaling pathway
cAMP signaling pathway
Dopaminergic synapsehsa04015:Rap1 signaling pathway
Dopaminergic synapse
Parkinson's disease
Cocaine addiction
Alcoholism
PANTHER Pathway 5HT2 type receptor mediated signaling pathwayP05912:Dopamine receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Dopamine receptor mediated signaling pathway
Nicotine pharmacodynamics pathway
Reactome Serotonin receptors
G alpha (q) signalling eventsR-HSA-390651:Dopamine receptors
G alpha (s) signalling eventsR-HSA-390651:Dopamine receptors
G alpha (i) signalling events
WikiPathways Serotonin Receptor 2 and STAT3 Signaling
Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
SIDS Susceptibility Pathways
Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
Gastrin-CREB signalling pathway via PKC and MAPK
GPCR ligand binding
GPCR downstream signaling
GPCRs, OtherWP58:Monoamine GPCRs
GPCR downstream signalingWP666:Hypothetical Network for Drug Addiction
Genes and (Common) Pathways Underlying Drug Addiction
Nicotine Activity on Dopaminergic Neurons
References
Ref 536463The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. Epub 2007 Jul 31.
Ref 536463The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. Epub 2007 Jul 31.